Antengene Corporation Limited (Antengene) has entered a global clinical collaboration with MSD (Merck & Co., Inc.) to evaluate the combination of ATG-022 and MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors. ATG-022 is a CLDN18.2-targeting antibody-drug conjugate (ADC). Data support meaningful efficacy across all levels of Claudin 18.2 expression in gastric cancer, including high, low, and ultra-low expressors. Antengene presented the late...